Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients — Stella

Home/ALK-positive Non-small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to ALK-positive Non-small Cell Lung Cancer trials

Trial locations(1 site)

China

Sichuan cancer hospital, Chengdu, Sichuan

Key details

Sponsor

Sichuan Cancer Hospital and Research Institute

Enrollment target

~200 participants

Started

May 2024

Primary completion

November 2026

Age range

18 Years and older

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.